SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Health Discovery Corp. – ‘8-K’ for 8/31/23

On:  Tuesday, 10/17/23, at 5:13pm ET   ·   For:  8/31/23   ·   Accession #:  1683168-23-7231   ·   File #:  333-62216

Previous ‘8-K’:  ‘8-K’ on 7/5/23 for 6/30/23   ·   Latest ‘8-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/17/23  Health Discovery Corp.            8-K:5,7     8/31/23   10:187K                                   GlobalOne Filings Inc/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 5: R1          Cover                                               HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- health_8k_htm                       XML     14K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- hdvy-20230831_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- hdvy-20230831_pre              XML     64K 
 2: EX-101.SCH  XBRL Schema -- hdvy-20230831                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    34K 
10: ZIP         XBRL Zipped Folder -- 0001683168-23-007231-xbrl      Zip     15K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
 i 0001141788  i false 0001141788 2023-08-31 2023-08-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  i August 31, 2023

 

 i HEALTH DISCOVERY CORPORATION

(Exact name of registrant as specified in charter)

 

 i GA    i 333-62216    i 74-3002154
(State of incorporation)   (Commission File Number)  

(IRS Employer

Identification No.)

 

 i 2002 SUMMIT BLVD,  i SUITE 300    
 i ATLANTA,  i GA    i 30319
(Address of principal executive offices)   (Zip Code)

  

 i (404)  i 566-4865

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i  Written communications pursuant to Rule 425 under the Securities Act.

 

 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

 i  Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

 

 i  Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(g) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
 i Common Stock, no par value  i HDVY N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

William F. Fromholzer, at the age of 77, will retire from the board of directors of Health Discovery Corporation (the “Company”) by October 1, 2023. Mr. Fromholzer issued the following statement: “My tenure as a director was one of the great experiences of my career and I look forward to watching the Company continue to move forward with SVM-RFE in the world of AI and in the development of identifying early stage diagnostics for common health issues.”

 

Item 7.01 Regulation FD Disclosure.

 

On August 31, 2023, Health Discovery Corporation (the “Company”) agreed to the terms of a settlement agreement for the patent infringement claims asserted against Intel Corporation in Health Discovery Corporation v. Intel Corporation, Case Nos. 6:20-cv-00666-ADA (W.D. Tex.), 6:20-cv-00356-ADA (W.D. Tex.). The agreement provides for the payment of $2,250,000 by Intel Corporation to the Company and release and dismissal of all claims against Intel Corporation with prejudice. A stipulation of dismissal was filed on September 15, 2023, and all asserted claims were dismissed with prejudice on September 18, 2023.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  HEALTH DISCOVERY CORPORATION
  Registrant

 

 

 
Dated:  October 17, 2023 By: /s/ Colleen Hutchinson
   

Colleen Hutchinson

Board Member

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:10/17/23None on these Dates
10/1/23
9/18/23
9/15/23
For Period end:8/31/23
 List all Filings 
Top
Filing Submission 0001683168-23-007231   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 7:45:37.1am ET